Tocilizumab is recommended for the treatment of severe COVID-19

Tocilizumab is recommended for the treatment of severe COVID-19

Bibliographic Details
Main Authors:	Yonggang Zhou, Haiming Wei
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396420304217

Similar Items

Why tocilizumab could be an effective treatment for severe COVID-19?
by: Binqing Fu, et al.
Published: (2020-04-01)

Efficacy of tocilizumab treatment in severely ill COVID-19 patients
by: Jie Zhao, et al.
Published: (2020-08-01)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
by: Piotr Zielecki, et al.
Published: (2020-09-01)

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
by: Tariq Kewan, et al.
Published: (2020-07-01)

The use of different formulations of tocilizumab in the treatment of patients with moderate to severe COVID-19
by: E. I. Veselova, et al.
Published: (2021-02-01)

Treatment of the Patient with COVID-19 Pneumonia with Tocilizumab
by: Özgür GÜNAL, et al.
Published: (2020-06-01)

Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
by: Alexandra A. Taube, et al.
Published: (2020-09-01)

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)
by: Marta Colaneri, et al.
Published: (2020-05-01)

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
by: Malgorzata Mikulska, et al.
Published: (2020-01-01)

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
by: Abeer Al-Baadani, et al.
Published: (2021-08-01)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
by: Shohei Shinomiya, et al.
Published: (2021-02-01)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
by: Tom van Kraaij, et al.
Published: (2020-04-01)

Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report
by: Alexandra Cristina Senegaglia, et al.
Published: (2021-06-01)

Successful treatment of a critical COVID-19 patient with tocilizumab
by: Shih-Ming Tsao, et al.
Published: (2021-05-01)

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia
by: Yojana Gokhale, et al.
Published: (2020-07-01)

Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis
by: Qiu Wei, et al.
Published: (2021-05-01)

Tocilizumab and liver injury in patients with COVID-19
by: Gaetano Serviddio, et al.
Published: (2020-10-01)

Appropriate use of tocilizumab in COVID-19 infection
by: Şiran Keske, et al.
Published: (2020-10-01)

Candidemia in COVID‐19 treated with corticosteroids and tocilizumab
by: Koichiro Yamamoto, et al.
Published: (2021-09-01)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
by: Annette Langer-Gould, et al.
Published: (2020-10-01)

Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01)

Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
by: Luis Sarabia De Ardanaz, et al.
Published: (2021-07-01)

Efficacy of tocilizumab treatment in COVID-19 patients with cytokine release syndrome
by: Hayat Kumbasar, et al.
Published: (2021-03-01)

Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
by: Zarębska-Michaluk D, et al.
Published: (2021-07-01)

Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study
by: Antonio Mastroianni, et al.
Published: (2020-07-01)

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
by: Antoniadou, C., et al.
Published: (2022)

Tocilizumab for severe COVID-19 related illness – A community academic medical center experience
by: Kapil S Meleveedu, et al.
Published: (2020-12-01)

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19
by: Tzu-Yi Chuang, et al.
Published: (2021-02-01)

Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19
by: O. V. Zhukova, et al.
Published: (2021-04-01)

Effekt av tocilizumab hos COVID-19 patienter
by: Haidari, Shegofa
Published: (2021)

Tocilizumab treatment and outcomes in severe COVID-19 patients: Retrospective study from a tertiary care institute in western India
by: Peta RK, et al.
Published: (2020-12-01)

The effects of tocilizumab on clinical and laboratory features of patients with severe COVID-19: a single-center experience
by: Zhamalbek I. Ashimov, et al.
Published: (2020-11-01)

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
by: Avi Gurion Kaye, et al.
Published: (2020-11-01)

Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
by: Manuel Rubio-Rivas, et al.
Published: (2020-12-01)

Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study
by: Benjamin Rossi, et al.
Published: (2020-10-01)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
by: Cristina de la Calle, et al.
Published: (2021-04-01)

Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm
by: Chuang Guo, et al.
Published: (2020-08-01)

Tocilizumab as a Treatment for ‘Cytokine Storm Syndrome’ in COVID-19: A Case Report
by: Ari Fahrial Syam, et al.
Published: (2021-07-01)

Successful Treatment of a COVID-19 Case with Pneumonia and Renal Injury Using Tocilizumab
by: Yugo Ashino, et al.
Published: (2020-10-01)

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
by: Edmund Huang, et al.
Published: (2021-04-01)